Camurus AB (publ)
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more
Camurus AB (publ) (CAMRF) - Net Assets
Latest net assets as of June 2025: $3.87 Billion USD
Based on the latest financial reports, Camurus AB (publ) (CAMRF) has net assets worth $3.87 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.42 Billion) and total liabilities ($553.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.87 Billion |
| % of Total Assets | 87.49% |
| Annual Growth Rate | 38.85% |
| 5-Year Change | 288.19% |
| 10-Year Change | 413.57% |
| Growth Volatility | 129.61 |
Camurus AB (publ) - Net Assets Trend (2014–2024)
This chart illustrates how Camurus AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Camurus AB (publ) (2014–2024)
The table below shows the annual net assets of Camurus AB (publ) from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.29 Billion | +120.34% |
| 2023-12-31 | $1.49 Billion | +50.10% |
| 2022-12-31 | $994.67 Million | +17.17% |
| 2021-12-31 | $848.91 Million | +0.17% |
| 2020-12-31 | $847.44 Million | +34.17% |
| 2019-12-31 | $631.63 Million | +150.33% |
| 2018-12-31 | $252.32 Million | -34.46% |
| 2017-12-31 | $385.00 Million | -31.79% |
| 2016-12-31 | $564.42 Million | -11.89% |
| 2015-12-31 | $640.56 Million | +418.85% |
| 2014-12-31 | $123.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Camurus AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 294.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $3.41 Billion | 103.80% |
| Total Equity | $3.29 Billion | 100.00% |
Camurus AB (publ) Competitors by Market Cap
The table below lists competitors of Camurus AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guizhou Space Appliance Co Ltd
SHE:002025
|
$2.11 Billion |
|
Wuchan Zhongda Group Co Ltd
SHG:600704
|
$2.11 Billion |
|
Chongqing Zongshen Power Machinery Co Ltd
SHE:001696
|
$2.11 Billion |
|
Hisamitsu Pharmaceutical Co. Inc
F:HPX
|
$2.11 Billion |
|
Solaris Oilfield Infrastructure Inc
F:68S
|
$2.10 Billion |
|
BaoViet Holdings
VN:BVH
|
$2.10 Billion |
|
Zhejiang Sanmei Chemical Industry Co Ltd
SHG:603379
|
$2.10 Billion |
|
PUBLIC STORAGE PRF.O 25
F:PUP0
|
$2.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Camurus AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,493,001,000 to 3,289,681,000, a change of 1,796,680,000 (120.3%).
- Net income of 428,394,000 contributed positively to equity growth.
- Share repurchases of 76,000 reduced equity.
- New share issuances of 1,311,525,000 increased equity.
- Other factors increased equity by 56,837,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $428.39 Million | +13.02% |
| Share Repurchases | $76.00K | -0.0% |
| Share Issuances | $1.31 Billion | +39.87% |
| Other Changes | $56.84 Million | +1.73% |
| Total Change | $- | 120.34% |
Book Value vs Market Value Analysis
This analysis compares Camurus AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.84x to 1.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $15.63 | $59.98 | x |
| 2021-12-31 | $15.48 | $59.98 | x |
| 2022-12-31 | $17.95 | $59.98 | x |
| 2023-12-31 | $26.84 | $59.98 | x |
| 2024-12-31 | $55.87 | $59.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Camurus AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.02%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.94%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.14x
- Recent ROE (13.02%) is above the historical average (-15.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 39.16% | 23.22% | 1.00x | 1.68x | $36.00 Million |
| 2015 | -24.91% | -103.06% | 0.19x | 1.27x | $-223.60 Million |
| 2016 | -14.35% | -71.21% | 0.18x | 1.13x | $-137.43 Million |
| 2017 | -49.50% | -350.91% | 0.11x | 1.24x | $-229.07 Million |
| 2018 | -93.01% | -475.81% | 0.14x | 1.45x | $-259.91 Million |
| 2019 | -45.89% | -274.48% | 0.14x | 1.22x | $-353.03 Million |
| 2020 | -19.74% | -49.78% | 0.32x | 1.23x | $-252.01 Million |
| 2021 | -10.65% | -15.06% | 0.56x | 1.27x | $-175.34 Million |
| 2022 | 5.59% | 5.81% | 0.73x | 1.31x | $-43.91 Million |
| 2023 | 28.90% | 25.13% | 0.90x | 1.28x | $282.14 Million |
| 2024 | 13.02% | 22.94% | 0.50x | 1.14x | $99.43 Million |
Industry Comparison
This section compares Camurus AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Camurus AB (publ) (CAMRF) | $3.87 Billion | 39.16% | 0.14x | $2.10 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |